A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
ALX Oncology Inc.
R-Pharm
Dispatch Biotherapeutics
Context Therapeutics Inc.
Kivu Bioscience Inc.
Taizhou Hanzhong biomedical co. LTD
Servier
Pfizer
Novartis
Kumquat Biosciences Inc.
Seagen Inc.
Seagen Inc.
Seagen Inc.
Pliant Therapeutics, Inc.
Pfizer
Eli Lilly and Company
AstraZeneca
Pfizer
IDEAYA Biosciences
Merck Sharp & Dohme LLC
Compass Therapeutics
Bristol-Myers Squibb
ExThera Medical Corporation
Aurigene Discovery Technologies Limited
BioNTech SE
Eli Lilly and Company
BioNTech SE
Eli Lilly and Company
Teclison Ltd.
Kivu Bioscience Inc.
Incyte Corporation
BioNTech SE
Genentech, Inc.
AstraZeneca
Boehringer Ingelheim
AbbVie
MOMA Therapeutics
Astellas Pharma Inc
Exero Medical Ltd.
Novartis
Kura Oncology, Inc.
Boehringer Ingelheim
Hoffmann-La Roche
Pfizer
Takeda
Janssen Research & Development, LLC
7 Hills Pharma, LLC
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)